AbbVie (NYSE:ABBV) Upgraded at Wall Street Zen

03 Mar 2026, 02:08 by Scott Moore · The Cerbat Gem

Wall Street Zen upgraded shares of AbbVie (NYSE:ABBV – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

Several other equities research analysts have also commented on the company. Berenberg Bank set a $275.00 price target on AbbVie in a research note on Tuesday, January 20th. Scotiabank began coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company. BMO Capital Markets restated an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, Piper Sandler increased their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $253.15.

View Our Latest Analysis on AbbVie

AbbVie Stock Performance

ABBV opened at $234.16 on Friday. AbbVie has a 1 year low of $164.39 and a 1 year high of $244.81. The company’s 50 day simple moving average is $224.47 and its 200 day simple moving average is $223.47. The stock has a market capitalization of $414.04 billion, a PE ratio of 99.22, a P/E/G ratio of 0.81 and a beta of 0.34.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the firm posted $2.16 earnings per share. AbbVie’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts expect that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.08% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Ellenbecker Investment Group grew its holdings in AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after acquiring an additional 44 shares during the period. Bank of Jackson Hole Trust increased its stake in shares of AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after acquiring an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA increased its stake in shares of AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after acquiring an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC boosted its stake in AbbVie by 0.3% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after acquiring an additional 45 shares during the last quarter. Finally, Centennial Wealth Advisory LLC raised its holdings in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after purchasing an additional 45 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.